title: Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
abstract: The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the adverse effects of treatments. However, there is no generally accepted quality of life instrument for use with this patient group. This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients' quality of life. The review also provides a narrative description of the evolving role of quality of life measures in clinical trials, and critiques the most widely used instruments.
authors.affiliation: Division of Urologic Surgery and Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina 22710, USA. judd.moul@duke.edu
authors.forename: Judd W
authors.initials: JW
authors.lastname: Moul
authors.forename: Nancy
authors.initials: N
authors.lastname: Dawson
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D018450:Disease Progression; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013534:Survival; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D017430:Prostate-Specific Antigen